These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36224497)

  • 1. Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2.
    Peng Q; Zhou R; Liu N; Wang H; Xu H; Zhao M; Yang D; Au KK; Huang H; Liu L; Chen Z
    Cell Mol Immunol; 2022 Nov; 19(11):1302-1310. PubMed ID: 36224497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity.
    Kuzmina A; Wattad S; Engel S; Rosenberg E; Taube R
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
    Cao Y; Yisimayi A; Bai Y; Huang W; Li X; Zhang Z; Yuan T; An R; Wang J; Xiao T; Du S; Ma W; Song L; Li Y; Li X; Song W; Wu J; Liu S; Li X; Zhang Y; Su B; Guo X; Wei Y; Gao C; Zhang N; Zhang Y; Dou Y; Xu X; Shi R; Lu B; Jin R; Ma Y; Qin C; Wang Y; Feng Y; Xiao J; Xie XS
    Cell Res; 2021 Jul; 31(7):732-741. PubMed ID: 34021265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
    Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
    J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain.
    Wu J; Nie J; Zhang L; Song H; An Y; Liang Z; Yang J; Ding R; Liu S; Li Q; Li T; Cui Z; Zhang M; He P; Wang Y; Qu X; Hu Z; Wang Q; Huang W
    Signal Transduct Target Ther; 2022 Jan; 7(1):18. PubMed ID: 35046385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.
    Wu J; Zhang L; Zhang Y; Wang H; Ding R; Nie J; Li Q; Liu S; Yu Y; Yang X; Duan K; Qu X; Wang Y; Huang W
    Front Immunol; 2021; 12():687869. PubMed ID: 34220844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.